Abstract | BACKGROUND: METHODS: We retrospectively studied 11 patients with metastatic gastrinomas followed for a mean period of 6 years. All patients were symptomatically treated with PPIs, and 9 of 11 patients received monthly injections of SSAs; all patients had an Eastern Cooperative Oncology Group score of 0-1, and received PRRT ((90) Yttrium- or (177) Lutetium- DOTATOC) for progressive disease. Serum gastrin measurements and radiological assessment (using the Response Evaluation Criteria in Solid Tumors criteria) were performed before and every 3-6 months following PRRT. RESULTS: PRRT induced symptomatic improvement in all patients. The mean serum gastrin decreased significantly from 4831 mI/L to 932.6 mI/L (normal, 40-108 mI/L; P < .001). Periodic radiological surveillance showed complete response in 1 (9%) patient, partial tumor response in 5/11 (45%) patients, and tumor stabilization in 5/11 (45%) patients. In 7/11 (64%) patients, the antitumor effect of PRRT persisted after a median period of 14 months. Four of 11 (36%) patients died due to tumor progression (median time to progression, 11 months); in this group, the mean survival time after the last PRRT was 14 ± 6.9 months. CONCLUSIONS: PRRT seems to be a promising tool for the management of patients with inoperable or progressive metastatic gastrinomas.
|
Authors | Simona Grozinsky-Glasberg, Dganit Barak, Merav Fraenkel, Martin A Walter, Jan Müeller-Brand, Joseph Eckstein, Liat Applebaum, Ilan Shimon, David J Gross |
Journal | Cancer
(Cancer)
Vol. 117
Issue 7
Pg. 1377-85
(Apr 01 2011)
ISSN: 0008-543X [Print] United States |
PMID | 21425137
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2010 American Cancer Society. |
Chemical References |
- Radioisotopes
- Receptors, Peptide
- Yttrium Radioisotopes
- Lutetium
- Octreotide
- Edotreotide
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Disease Progression
- Female
- Gastrinoma
(diagnostic imaging, pathology, therapy)
- Humans
- Lutetium
(therapeutic use)
- Male
- Middle Aged
- Neoplasm Metastasis
- Octreotide
(analogs & derivatives, therapeutic use)
- Radioisotopes
(therapeutic use)
- Receptors, Peptide
(therapeutic use)
- Retrospective Studies
- Tomography, X-Ray Computed
- Treatment Outcome
- Yttrium Radioisotopes
(therapeutic use)
|